#	Pagina
attuale pagina	/open-h2020/projects/215465/index.html
-1	/open-h2020/projects/211883/index.html
-2	/open-h2020/projects/196424/index.html
-3	/open-h2020/projects/209755/index.html
-4	/open-h2020/projects/198071/index.html
-5	/open-h2020/projects/219881/index.html
-6	/open-h2020/projects/195432/index.html
-7	/open-h2020/projects/195824/index.html
-8	/open-h2020/projects/198948/index.html
-9	/open-h2020/projects/195710/index.html
-10	/open-h2020/projects/195918/index.html

Opendata, web and dolomites

FluPRINT SIGNED

Tracing the inFLUenza vaccine imPRINT on immune system to identify cellular signature of protection

Total Cost €

EC-Contrib. €

Partnership

Views

FluPRINT project word cloud

Explore the words cloud of the FluPRINT project. It provides you a very rough idea of what is the project "FluPRINT" about.

progress blood vaccine source children advantage hospitalized burden signatures protection variability cohorts 2015 public tools raised clinical 2010 algorithms vaccines imprint exist immunity susceptibility health learning generation obstacles inactivated predictive attenuated additional recommended adaptive had cellular finland influenza immune opened termed received socioeconomic season shedding virus society uk discrepancy stimulation small population effectiveness immunological 1000 biology laiv sponsors lack volumes cdc licensed elderly deaths investigation group tracing correlates basis 2016 cell machine hampered poor causes fluprint vaccination infection iiv live did levels spread limited

Project "FluPRINT" data sheet

The following table provides information about the project.

Coordinator	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	United Kingdom [UK]
Total cost	269˙857 €
EC max contribution	269˙857 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2017
Funding Scheme	MSCA-IF-GF
Starting year	2018
Duration (year-month-day)	from 2018-06-01 to 2021-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	coordinator	269˙857.00
2	BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Organization address address: SERRA MALL 450 city: STANFORD postcode: 94305 2004 website: www.stanford.edu contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	US (STANFORD)	partner	0.00

Map

Project objective

Influenza virus causes a large socioeconomic burden on society, with 70 000 deaths every year in Europe. It is estimated that 1 in 1000 children and elderly every year are hospitalized due to influenza infection. Children, due to high susceptibility and high levels of shedding, are the main source of spread of the virus. Therefore, CDC in 2010 included children as a high priority group for influenza vaccination. Two influenza vaccines are licensed: inactivated (IIV) and live attenuated (LAIV) vaccine. The LAIV was introduced to provide broader protection by additional stimulation of T cell responses. At present the two major obstacles in the widespread use of LAIV are concerns raised over vaccine effectiveness and the lack of immunological correlates of protection. In 2016 the CDC in the US recommended against the use of LAIV due to its poor effectiveness in the 2015/2016 season. However, the same vaccine, in the same season had high effectiveness as assessed by UK and Finland public health authorities. Currently the reason for this discrepancy is not known. This project will take advantage of cohorts of children who have received LAIV provided by both US and UK sponsors, to investigate the immunological basis for the observed variability and to define the role of adaptive immunity by applying the systems biology tools and machine learning algorithms for predictive modelling. Progress in the clinical investigation of children has been hampered by limited methods that could be applied to the small blood volumes, but recent advances in systems biology have opened new opportunities that did not exist before. Tracing the influenza vaccine imprint on immune system, termed FluPRINT by the proposed project will help to identify cellular signatures of vaccine-induced protection in children which is of importance for the development of next generation of influenza vaccines that will be more effective in this target population.

Publications

List of publications.
year	authors and title	journal	last update
2019	Adriana Tomic, Ivan Tomic, Yael Rosenberg-Hasson, Cornelia L. Dekker, Holden T. Maecker, Mark M. Davis SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine Responses published pages: ji1900033, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900033	The Journal of Immunology	2019-09-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FLUPRINT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FLUPRINT" are provided by the European Opendata Portal: CORDIS opendata.